Schulke India Private Limited
Case brief
What is this about?
The Competition Commission of India evaluated a proposed acquisition of Ethicon's healthcare antisepsis solutions business by Schulke Germany. After analyzing market shares and overlapping business activities in India, the Commission found no appreciable adverse effect on competition and approved the merger.
What did the court decide?
Combination approved under Section 31(1) of the Competition Act, 2002 with a proviso regarding correction of false information.
What the court decided
A compact analysis
This page shows the compact analysis of this judgement. The full analysis — procedural history, issue-by-issue holdings with ratio and obiter, advocates, and paragraph-level evidence for every claim — is being added to the record in batches and will appear here when this judgement has been through it.
Fair Competition For Greater Good
COMPETITION COMMISSION OF INDIA
(Combination Registration No.C-2015/12/349)
15.01.2016
Notice filed by Schulke & Mayr GmbH (“Schulke Germany”)
Order under sub-section (1) of Section 31 of the Competition Act, 2002 (“Act”)
CORAM:
Mr. S. L. Bunker Member
Mr. Sudhir Mital
Member
Mr. Augustine Peter Member
Mr. U. C. Nahta Member
Mr. G. P. Mittal Member
Issues for consideration
3 issues framed by the court
Whether the proposed combination constitutes a concentration under Section 5 of the Act in the market for Human A&D Products in India.
Whether the acquisition is likely to cause an appreciable adverse effect on competition in India.
Whether the Commission should approve the combination under Section 31(1) of the Act.
Parties & counsel
- applicant
Schulke & Mayr GmbH
Coram
Mr. S. L. Bunker
Mr. Sudhir Mital
Mr. Augustine Peter
Case details
As recorded by the court registry
All orders in this case
2 orders share this CNR
- Order 1 — this page
- Order 2
Similar cases
Judgements on the same questions, provisions and authorities, from every court